Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods. The company operates through Brands, Distribution, and Original Equipment Manufacture segments. It provides various complementary medicines for bone and joint, children, diabetic, heart, herbal, liver and digestive, skin, slimming, and well-being care, as well as men's and women's care products and sports supplements; gastrointestinal and pain care OTC medicines; and prescription medicines in the areas of iron supplement, anticoagulant, diabetology, cardiology, dermatology, gastroenterology, neurology, pain, osteoporosis, respiratory, urology, oncology, and nephrology. The company also offers logistical and marketing services for the sale of goods manufactured by third parties. In addition, the company engages in the operation of wellness center; and software design, development, and other services business. It operates in the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited.
Mega Lifesciences Dividend Announcement
• Mega Lifesciences announced a semi annually dividend of ฿0.80 per ordinary share which will be made payable on 2024-09-10. Ex dividend date: 2024-08-23
• Mega Lifesciences annual dividend for 2024 was ฿1.60
• Mega Lifesciences annual dividend for 2023 was ฿1.65
• Mega Lifesciences's trailing twelve-month (TTM) dividend yield is 4.6%
• Mega Lifesciences's payout ratio for the trailing twelve months (TTM) is 75.60%
• Mega Lifesciences's dividend growth over the last five years (2018-2023) was 18.37% year
Mega Lifesciences Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-08-23 | ฿0.80 | semi annually | 2024-09-10 |
2024-03-06 | ฿0.80 | semi annually | |
2023-08-24 | ฿0.80 | semi annually | 2023-09-08 |
2023-03-08 | ฿0.85 | semi annually | 2023-04-24 |
2022-08-24 | ฿0.75 | semi annually | 2022-09-09 |
2022-03-08 | ฿0.86 | semi annually | 2022-04-22 |
2021-08-27 | ฿0.52 | semi annually | 2021-09-14 |
2021-03-08 | ฿0.54 | semi annually | 2021-04-23 |
2020-08-27 | ฿0.36 | semi annually | 2020-09-11 |
2020-03-09 | ฿0.41 | semi annually | 2020-04-28 |
2019-08-28 | ฿0.31 | semi annually | 2019-09-13 |
2019-03-11 | ฿0.40 | semi annually | 2019-04-29 |
2018-08-28 | ฿0.31 | semi annually | 2018-09-13 |
2018-03-09 | ฿0.40 | semi annually | 2018-04-27 |
2017-08-25 | ฿0.30 | semi annually | 2017-09-13 |
2017-03-08 | ฿0.24 | semi annually | 2017-04-28 |
2016-08-23 | ฿0.23 | semi annually | |
2016-03-09 | ฿0.24 | semi annually | |
2015-08-26 | ฿0.16 | semi annually | |
2015-03-09 | ฿0.25 | semi annually | |
2014-08-26 | ฿0.10 | semi annually | |
2014-04-24 | ฿0.18 | semi annually |
Mega Lifesciences Dividend per year
Mega Lifesciences Dividend growth
Mega Lifesciences Dividend Yield
Mega Lifesciences current trailing twelve-month (TTM) dividend yield is 4.6%. Interested in purchasing Mega Lifesciences stock? Use our calculator to estimate your expected dividend yield:
Mega Lifesciences Financial Ratios
Mega Lifesciences Dividend FAQ
Other factors to consider when evaluating Mega Lifesciences as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Mega Lifesciences stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Mega Lifesciences's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Mega Lifesciences publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Mega Lifesciences distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Mega Lifesciences are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Mega Lifesciences sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Mega Lifesciences distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Mega Lifesciences declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Mega Lifesciences's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Mega Lifesciences's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.